Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

No-match ORESTES explored as tumor markers

Full text
Mello, Barbara P. [1] ; Abrantes, Eduardo F. [1] ; Torres, Cesar H. [1] ; Machado-Lima, Ariane [2] ; Fonseca, Rogrio da Silva [1] ; Carraro, Dirce M. [1] ; Brentani, Ricardo R. [1] ; Reis, Luiz F. L. [1] ; Brentani, Helena [1]
Total Authors: 9
[1] Hosp AC Camargo Fund Antonio Prudente, BR-01509900 Sao Paulo - Brazil
[2] Univ Sao Paulo, IPq, IME, BR-05508090 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Nucleic Acids Research; v. 37, n. 8, p. 2607-2617, MAY 2009.
Web of Science Citations: 9

Sequencing technologies and new bioinformatics tools have led to the complete sequencing of various genomes. However, information regarding the human transcriptome and its annotation is yet to be completed. The Human Cancer Genome Project, using ORESTES (open reading frame EST sequences) methodology, contributed to this objective by generating data from about 1.2 million expressed sequence tags. Approximately 30 of these sequences did not align to ESTs in the public databases and were considered no-match ORESTES. On the basis that a set of these ESTs could represent new transcripts, we constructed a cDNA microarray. This platform was used to hybridize against 12 different normal or tumor tissues. We identified 3421 transcribed regions not associated with annotated transcripts, representing 83.3 of the platform. The total number of differentially expressed sequences was 1007. Also, 28 of analyzed sequences could represent noncoding RNAs. Our data reinforces the knowledge of the human genome being pervasively transcribed, and point out molecular marker candidates for different cancers. To reinforce our data, we confirmed, by real-time PCR, the differential expression of three out of eight potentially tumor markers in prostate tissues. Lists of 1007 differentially expressed sequences, and the 291 potentially noncoding tumor markers were provided. (AU)